July 10, 2025

Trial by fire

Hi there,

Here is this week's Hot or Not.

Hot: Google’s human trials

Alphabet subsidiary Isomorphic Labs is preparing to test its AI-designed cancer drugs in humans per comments from President Colin Murdoch this week.

The company, a Google DeepMind spinoff, raised $600M in March 2025.

Oncology is a key focus across the pharma landscape: the therapeutic area dominates one-third of all pharma AI partnerships.

See which pharma companies are leading the AI charge in CB Insights' Pharma AI Readiness Index.

Not: AI coding pricing 

AI coding tools are coming under pricing pressure.

This week, Cursor's coding environment switched from unlimited usage to a $20 monthly credit system, catching users off guard when they burned through credits after a few prompts with expensive models like Claude Opus 4. In June, users of Replit — another AI coding tool — were also affected by price hikes from the company’s new effort-based pricing.

Cursor (with $500M in ARR) and Replit are 2 frontrunners out of the 92 companies CB Insights tracks in the coding AI agents & copilots market.

As these companies vie for market share, they face a pricing squeeze from two directions: they must pass through model costs from providers like Anthropic and OpenAI, while competing against those same providers (see Anthropic’s Claude Code). 

CB Insights customers can get the full breakdown of the coding AI agents & copilots market on the CBI platform.

Hot: AI-powered eyewear 

Meta is cementing its wearable push: the giant took a $3.5B stake in Ray-Ban maker EssilorLuxottica this week. 

Similarly, Google announced deals with Gentle Monster and Warby Parker for Android XR glasses earlier this year.

Both tech giants are making a play at securing the next computing platform: whoever controls the eyewear interface controls ambient computing's future.

The competitive landscape is heating up fast. News mentions of AI wearable-related terms are surging, reflecting growing market interest and investor attention as the industry prepares for further adoption.

Track how Meta's eyewear strategy stacks up against Google's moves with CB Insights' Competitive Sentinel.

Not: Cloud vendor loyalty 

OpenAI's $30B annual Oracle cloud deal signals the death of single-vendor dependency in AI infrastructure. 

The generative AI leader is simultaneously running workloads across Oracle, Microsoft Azure, CoreWeave, and Google Cloud.

This multi-cloud strategy reflects a broader shift as AI companies prioritize capacity over loyalty to meet the scale demands of frontier AI development.

For cloud providers, this means the AI gold rush isn't winner-take-all — the big 3 all continue to report double-digit revenue growth. 

Get the breakdown on their AI strategies here.

The +1

Source: u​​/Potential-Focus3211 via Reddit

Clean Air, Unclear Chart. This pollution map forgot its legend. Guess the toxin.

I love you.

Anand

@asanwal 

Co-Founder & Exec Chair

P.S. Want to know what’s driving Q2'25 venture trends? Join our State of Venture Q2'25: Midyear Outlook briefing — register here.

Exclusive Startup Access: 75% Off CB Insights

CB Insights' emerging technology insights platform provides all the analysis and data from this newsletter. Our data is the easiest way to discover and respond to emerging tech. 

Was this email forwarded to you? Sign up here